Mirai Bio
1 known investors
Find your way into Mirai Bio
Mirai Bio develops lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, combining cargo design, proprietary lipid chemistry, cell-specific targeting, in vivo evaluation, and manufacturability into a single development process. It works with partners across modalities such as mRNA, siRNA, self-amplifying RNA, circular RNA, gene-editing cargo, and DNA-based approaches to address delivery challenges and reach previously inaccessible tissues.
Founders & leadership
KT
Kate TorchilinPresident & CEO
Investors · 1
In the news
Frequently asked questions
- What does Mirai Bio do?
- Mirai Bio develops lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, combining cargo design, proprietary lipid chemistry, cell-specific targeting, in vivo evaluation, and manufacturability into a single development process. It works with partners across modalities such as mRNA, siRNA, self-amplifying RNA, circular RNA, gene-editing cargo, and DNA-based approaches to address delivery challenges and reach previously inaccessible tissues.
- Who are Mirai Bio's investors?
- Mirai Bio's investors include Flagship Pioneering.